Latest Healthcare News

SomnoMed reports a strong start to FY26 with 13.5% revenue growth and confirms the Clayton Sleep Institute as the first US site for its pivotal Rest Assure clinical study, backed by FDA protocol agreement.

Little Green Pharma reported a robust September quarter with revenue exceeding $10 million, driven by growth across all product lines and strong European market performance. The company is poised to benefit from upcoming regulatory reforms and operational efficiencies.

ImpediMed Limited reported a record A$3.6 million quarterly revenue and expanded its US hospital footprint with over 600 SOZO units installed. The launch of SOZO Pro targets new heart failure markets, while reimbursement coverage accelerates across US states.

Next Science reported a 3% rise in Q3 product sales and completed a $50 million asset sale to OSARTIS GmbH, setting the stage for a significant shareholder return.

Oneview Healthcare reported a €2.2 million net cash outflow in Q3 2025, impacted by delayed customer payments, while expanding its U.S. footprint with a new client and advancing deployments.

Cann Group Limited reported a near break-even net operating cash flow for Q1 FY2026 and achieved its first EBITDA-positive month, setting the stage for a major debt restructure that will significantly reduce its borrowings.

Tissue Repair Limited reports steady progress in its Phase 3 clinical trials for chronic wound treatment and advances regulatory filings for its TR Pro+® product, while gearing up for a major commercial rollout in early 2026.

Atomo Diagnostics reported strong commercial momentum in Q1 FY26, highlighted by a key FDA submission for its FebriDx test and a successful capital raise of $1.3 million. The company also showcased promising clinical data for its Active Syphilis test and expanded its HIV Self-Test distribution channels.

BlinkLab has completed its U.S. autism pilot study with strong diagnostic accuracy and expanded its pivotal FDA trial to seven leading research centers, positioning itself for regulatory submission in late 2026.

Austco Healthcare kicks off FY26 with a robust 51% revenue increase and improved profitability, driven by strong organic growth and strategic acquisitions.

Doctor Care Anywhere reports a 7.5% rise in consultations excluding secondary care and sustains positive cashflow for the second consecutive quarter, reaffirming ambitious medium-term growth targets.

Amplia Therapeutics reports encouraging interim results for narmafotinib in metastatic pancreatic cancer, alongside a successful capital raise and key patent allowance.